Brokerages Set Tyra Biosciences, Inc. (NASDAQ:TYRA) PT at $30.50

Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) have earned an average rating of “Buy” from the six ratings firms that are currently covering the stock, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average 12-month price target among brokerages that have covered the stock in the last year is $30.50.

Several analysts have recently weighed in on TYRA shares. UBS Group started coverage on shares of Tyra Biosciences in a research report on Tuesday, January 7th. They set a “buy” rating and a $28.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of Tyra Biosciences in a report on Tuesday, February 18th.

Insider Activity at Tyra Biosciences

In other Tyra Biosciences news, Director Nina S. Kjellson sold 7,779 shares of the business’s stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $16.29, for a total value of $126,719.91. Following the completion of the transaction, the director now directly owns 447,857 shares of the company’s stock, valued at approximately $7,295,590.53. The trade was a 1.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders sold 21,998 shares of company stock valued at $344,818 in the last ninety days. Insiders own 15.40% of the company’s stock.

Hedge Funds Weigh In On Tyra Biosciences

A number of institutional investors have recently modified their holdings of the stock. RA Capital Management L.P. raised its stake in shares of Tyra Biosciences by 2.1% in the fourth quarter. RA Capital Management L.P. now owns 10,637,290 shares of the company’s stock worth $147,858,000 after acquiring an additional 220,681 shares during the last quarter. Alta Partners Management Company L.P. bought a new position in shares of Tyra Biosciences in the fourth quarter worth about $56,716,000. FMR LLC raised its stake in shares of Tyra Biosciences by 0.8% in the third quarter. FMR LLC now owns 3,372,850 shares of the company’s stock worth $79,296,000 after acquiring an additional 26,187 shares during the last quarter. Boxer Capital Management LLC bought a new position in shares of Tyra Biosciences in the fourth quarter worth about $28,185,000. Finally, Janus Henderson Group PLC raised its stake in shares of Tyra Biosciences by 63.6% in the fourth quarter. Janus Henderson Group PLC now owns 1,746,320 shares of the company’s stock worth $24,291,000 after acquiring an additional 679,124 shares during the last quarter. 84.14% of the stock is owned by institutional investors.

Tyra Biosciences Stock Performance

Shares of Tyra Biosciences stock opened at $10.95 on Wednesday. The firm’s 50-day simple moving average is $14.16 and its 200-day simple moving average is $17.78. Tyra Biosciences has a twelve month low of $10.65 and a twelve month high of $29.60. The firm has a market cap of $554.10 million, a P/E ratio of -6.80 and a beta of 1.05.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.